NCT03781063 2026-01-28Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 MutationSermonix Pharmaceuticals Inc.Phase 2 Completed100 enrolled